Introduction
Major Depressive Disorder (MDD) is a common mood disorder, affecting approximately 300 million people worldwide with an estimated lifetime prevalence rate of 5% to 19% in the general population 1, 2 . Though its molecular and cellular pathophysiology has not been completely elucidated, it has been suggested that nearly 50% of the risk for depression is contributed to genetic factors 3 . Overwhelming evidences have indicated that depression is associated with altered neuronal and structural plasticity and neurogenesis [4] [5] [6] [7] , or with an inability of the brain to make appropriate adaptive responses to environmental stimuli due to impaired synaptic plasticity [8] [9] [10] . Despite a tremendous amount of researches, the molecular and cellular mechanisms associated with the etiopathology of major depression are not clearly understood.
MicroRNAs (miRNAs, miR) regulate gene expression at the post-transcriptional level, playing a significant role in coordinating nervous system development and neuronal function in the mature brain. Amounting evidences have suggested that a relatively large number of miRNAs are expressed in the brain 11, 12 , and that they regulate gene expression during brain differentiation and development 13 , and in processes such as the establishment and maintenance of dendrites 14 and neurite outgrowth 15 . Altered expressions of miRNAs have been demonstrated to contribute to genetic and biological basis of neuropsychiatric disorders, particularly Huntington disease 16, 17 , Parkinson disease 18, 19 , and Tourette's syndrome 20 . Expression profiling studies in postmortem gray matter and peripheral blood samples of individuals with MDD have implicated numerous miRNAs [21] [22] [23] . It has been increasingly acceptable that aberrant expressions of certain miRNAs have a significant role in underlying pathophysiology of MDD. There have been a number of studies investigating into the role of altered miRNA expression in the molecular mechanism of depression. Xu et al. conducted an association analyses in 1088 MDD patients and 1102 control subjects from Chinese Han Population, and found that a polymorphism within miR-30e was positively correlated with depression and its symptomatic onset 21 . In a microarray screening study, Maussion et al. observed that an increase of miR-185 expression levels regulates, at least in part, the TrkB-T1 decrease observed in the frontal cortex of suicide completers, which was later validated by a larger sample of 38 suicides and 17 controls 24 . In another study, Smalheiser et al. measured the expression of miRNAs in prefrontal cortex of 18 antidepressant-free depressed suicide and 17 well-matched non-psychiatric control subjects using multiplex RT-PCR plates, and found widespread changes in miRNA expression that were likely to participate in pathogenesis of major depression and/or suicide 25 . These studies are suggesting that miRNAs are not only involved with the pathophysiology of depression, but also with the symptoms of depression. By far, the only symptom of depression patients that has been noted was suicidal behaviors. There has been a lack of evidences supporting the view that certain miRNAs correlate with certain symptomatologies.
We thus hypothesize that certain miRNAs correlate with certain symptomatologies in depression patients, and covariation exists between corresponding miRNA and symptomatology along the antidepressant treatment course. In this study, a total of 81 depression patients and 46 normal controls were enrolled for the microarray analysis, and 20 out of the 81 patients and their corresponding controls were selected for antidepressant treatment course to investigate into the alteration of miRNA expression and symptomatology improvement, in an effort to clinically validate certain miRNAs as specific blood-based therapeutic targets in depression patients.
Methods and materials

Participants
Ninety-one major Major Depressive Disorder (MDD) patients, aged from 15 to 68, fulfilling the criteria as defined by the Diag-nostic and Statistical Manual 4th edition (DSM-IV), were enrolled from No.102 Hospital of the Chinese People's Liberation Army (PLA) from Aug. 2012 to Oct. 2013. Clinical diagnoses of the patients were made by at least two psychiatrists, and the diagnoses were further confirmed by an additional experienced clinical psychiatrist. All patients were prior to any antidepressant or antipsychiatric treatment, or in the absence of antidepressant or antipsychiatric medication within at least 3 months. No patients had history of severe medical diseases, other psychiatric disorders, structural brain disorders, mental retardation, unstable psychiatric features and movement disorders. Also, patients who had brain injury causing traumatic amnesia longer than 24 hours and who received blood transfusion within a month or electroconvulsive therapy within 6 months, were excluded from the study. In addition, 46 healthy controls, aged from 15 to 68, without any family history of major psychiatric disorders (SZ, bipolar disorder and MDD) within the last three generations were recruited. Similarly, all healthy controls were without any history of blood transfusion or severe traumatic event within a month. All individuals enrolled in the study provided written informed consent. The study was approved by local Institutional Review Board.
Blood collection and RNA extraction
Whole blood (5 ml) was collected from each subject using EDTA anticoagulant tube and processed within 3 hours. Peripheral Blood Mononuclear Cells (PBMCs) were isolated from the blood by Ficoll density centrifugation, then transferred into fresh RNase/DNase-free 2 ml microcentrifuge tube, and stored at -80°C until use. Total RNAs were extracted from the PBMCs with the mirVana TM PARIS TM Kit (Applied Biosystems, p/nAM1556) according to the manufacturer's protocol, and were quantified by the NanoDrop ND-2100 (Thermo Scientific). The RNA integrity was assessed using Agilent 2100 (Agilent Technologies). To ensure a robust analysis for the following procedures, samples with an RNA integrity number (RIN) inferior to 8 were excluded.
MicroRNA microarray expression profiling
Total RNAs from three MDD patients (male, 30 years; male, 31 years; female, 28 years) and three controls (male, 30 years; male, 31years; female, 27 years) were used for miRNA microarray profiling. miRNA expression was measured by Affymetrix miRNA 3.0 array (Affymetrix, Santa Clara, CA, USA) containing probes for a total of 723 human miRNAs. The sample labeling, microarray hybridization and washing were performed based on the manufacturer's standard protocols. Briefly, total RNA were tailed with Poly A and then labeled with Biotin. After, the labeled RNAs were hybridized onto the microarray. Having washed and staining the slides, the arrays were scanned by the Affymetrix Scanner 3000 (Affymetrix). The scanned images were analyzed using Expression Console software (version1.3.1, Affymetrix).
Real-time quantitative reversetranscription PCR (qRT-PCR)
According to microarray results and literature, candidate miRNAs were chosen for further validation with real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR). Blood samples from 91 MDD patients were used to validate the findings from microRNA profiling. Total RNAs were isolated from the PBMCs using Trizol reagent (Invitrogen®, USA) for quantitative detection of miRNA. Complementary DNA was synthesized using the Reverse Transcription TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, inc., USA, P/N:4366596) according to the manufacturer's instructions. Each RT reaction consisted of 5 l of RNA, dNTP mix (100mM) 0.15 l, Multiscribe RT enzyme (50U/ l) 1.00ul, 10×RT Buffer 1.5 l, RNase Inhibitor 0.19ul, Nuclease free water 4.16 l, TaqMan MicroRNA Assays 3 l, in a total volume of 15 l. Reactions were performed using the following conditions: 30 min at 16ºC, 30 min at 42ºC, 5 min at 85ºC, and held at 4ºC. Realtime PCR was performed using Applied Biosystems 7900HT Real-Time PCR System (Applied Biosystems, Inc., USA), with 10 l PCR reaction mixture that included 2 l of the cDNA, 5 l of 2 × TaqMan Universal Master Mix II (Applied Biosystems, Inc.), 0.25 l of miRNA-specific primer/probe mix (Applied Biosystems, inc.), 0.5 l of TaqMan MicroRNA Assays (Applied Biosystems, CA) and 2.25 l of double distilled water. PCR reactions in a 384-well plate were run at 95ºC, for 10 min, followed by 40 cycles of 95ºC, for 15 s, 60ºC, for 1 min. Each sample was run in triplicate for analysis. The miRNA-specific stem-loop primers were supplied by the TaqMan MicroRNA Assays (Applied Biosystems, Inc.) based on the microRNA sequences obtained from the miRBase database. Data were collected using the SDS 2.3 software (Applied Biosystems, Inc.). After normalized to RNU48, the expression levels of microRNAs were calculated using the 2 -ΔCt method 26 .
Clinical symptomatology assessment instrument
Altogether three psychiatrists were responsible for scale assessment. Hamilton rating scale for depression (HAMD) and Clinical Global Impression (CGI) were used to assess the clinical symptoms of all patients before and six weeks after medication intervention. All three psychiatrists were collectively trained for unified procedure.
HAMD is a classic medical scale used for measuring symptom severity of MDD patients. It was published with three versions in 1960, namely the 17-item version, the 21-item version and the 24-item version 27 . The 24-item version of HAMD was used in this study. It covered 7 dimensions, including anxiety/somatization, body weight, cognitive disorder, day and night change, retardation, sleep disorder and hopelessness. In this study, we adopted the Chinese version of this scale, which has been naturalized and verified for its reliability and validity 28 . The total score and symptomatology scores were used for statistical analysis.
CGI was designed by WHO for measuring clinical treatment effects of any kind of psychiatric diseases 29 . Its reliability and validity also have been naturalized and verified 30 , applicable to Chinese people.
Clinical data collection and scales assessment
General information (including name, gender, age, ethnicity, education level, occupation, income level, marital status, substance abuse history and family history of psychotic diseases) from all subjects in the MDD group were collected. One attending doctor and two resident psychiatric doctors participated in evaluating illness severity and treatment effects, plus recording dosage information (including medication, dosage, side effects and treatment course) using HAMD and CGI. Likewise, the general information of healthy controls was also recorded. Procedures for data collection were standardized to ensure the accuracy of the collected data. The total score and factors score of HAMD and global improvement (GI) of CGI scale were used for statistical analysis.
Medication intervention
Twenty out of all MDD patients were selected by systematic random sampling for clinical intervention observation. A combination of medication were applied, including venlafaxine with dosage range from 150 mg to 225 mg, sertraline with dosage range from 50 mg to 150 mg and mitrazapine with dosage range from 22.5 mg to 45 mg, all of which are new-type antidepressants, inhibiting the reuptake of serotonin receptors and norepinephrine receptors and triggering less side effects.
Statistical analysis
All data were processed by SPSS v17.0. Real-time quantitative PCR data were collected by SDS software and relative levels of the tested miRNA in plasma were calculated based on the following formula using RNU48 as an internal reference: 2 -ΔCt (ΔCt = CtmiRNA -CtRUN48). Wilcoxon rank sum test was used to test the differences of 10 miRNA expression levels between MDD group and control group. Paried sample t test was used to test the differences of assessment scores by HAMD and CGI. Pearson correlation test was carried out for testing the correlation of miRNA expression level change with HAMD and CGI scores changes. Finally, logistic regression analysis was performed to determine the accountability of miRNA for symptomatology improvements. All statistical tests were two-tailed, and P < 0.05 was considered statistically significant.
Results
Demographic data of the MDD patients
Of the 91 MDD patients, 10 of them had hemolysis and showed a extremely high CT value of RNU48 (the internal normalization control), thus were removed for further analysis. So there were 81 cases left in MDD group for final analysis. The demographic data of the 81 MDD patients is shown in 
Microarray analysis
Microarray analysis result showed that a total of 26 miRNAs were identified as significantly different from the control group, with 5 increased and 21 decreased at P = 0.05 or better. According to Allison 31 , we selected the group of miRNAs by the means of microarray analysis. Ten of the 26 miRNAs were selected by the following standards: miRNAs with higher fold change in microarray results; miRNAs that had been reported in Public biological Biological databasesDatabases, such as GO, KEGG and BioCarta Pathways; miRNAs that could be detected in every sample.
Comparison of miRNA expression levels between MDD group and control group before medication
As is shown in Table 2 , wilcoxon rank sum test result revealed that the ΔCT values of 5 miRNAs (miR-26b, miR-4743, miR-4498, miR-4485, miR-1972) in MDD group were significantly lower than those of the control group (P < 0.05), which indicated the expression levels of these 5 miRNA were significantly higher than those of the control group as was computed by 2 -ΔCT .
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Comparison of HAMD score and its factor scores between before and after antidepressants treatment in MDD group As is shown in Table 4 , paired sample t test result demonstrated that the total score and most factor scores except body weight were significantly lower than those of control group (P < 0.05).
Correlation of miRNA expression alteration and HAMD and GI score changes before and after antidepressants treatment
As is shown in Table 5 , the ΔCt changes of miR-1972, miR-4485, miR-4498 and miRMicroRNA EXPRESSION AND MDD SYMPTOMATOLOGY 259 Table 3 Comparison of miRNA expression levels between different genders, ages and residential locations in the MDD group before medication (x ± S). 4743 were positively correlated with the improvement of retardation (P < 0.05); the ΔCt changes of miR-26b was negatively correlated with the improvement of day and night change symptom (P < 0.05). The ΔCt changes of any miRNA was not significantly correlated with GI improvement (P < 0.05).
Genders
Logistic regression analysis of the effects of miRNA expression alteration upon certain symptomatology improvement
Taking the expression alteration of miRNA as independent variable, and the treating effect of retardation and day and night change as dichotomous dependent variable, logistic regression analysis was carried out to verify the association between miRNA expression alteration and symptomatology improvement. The treating effect was determined by score reduction rate (Spre-Spost/Spre, Spre represents pre-medication score, Spost represents post-medication score). Score reduction rate less than 0.5 was taken as low treating effect, and score reduction rate more than 0.5 as high treating effect. As Table 6 indicates, ΔmiR-4498 was entered into the regression function with retardation factor as independent variable, accounting for 28.8% of retardation improvement (P < 0.05). On the other hand, the analysis result of logistic regression with day and night change factor as independent variable was insignificant (P > 0.05).
Discussion
Currently, pharmacological treatments for MDD mainly involve SSRI, pharmacological mechanism of which remains elusive, which makes it impossible to customize treatment and predict treatment effects. In recent years, the emerging trend of miRNA research had made it possible to tap the potential of manipulating miRNAs as a strategy for novel antipsychotic development 32, 33 . Some studies have reported that certain drugs could alter miRNA expression. Zhou et al. investigated hippocampal miRNA expression changes following chronic treatment with lithium and valproate, and found 37 differentially expressed miRNAs in lithium group and 31 differentially expressed miRNAs in valproate 260 QIAO-LI ZHANG ET AL. Table 4 Comparison of HAMD score and its factor scores between before and after antidepressants treatment in MDD group (x ± S).
Items
Before medication (n = 20) 36 . Bocchio-Chiavetto et al. conducted a whole-miRNome quantitative analysis with qRT-PCR of the changes in the blood of 10 depressed subjects after 12 weeks of treatment with escitalopram, and found that 30 miRNAs were differentially expressed after the AD treatment: 28 miRNAs were upregulated, and 2 miRNAs were strongly down-regulated 37 . However, there is hardly any study so far that focuses on the association between the changes of miRNA expression and the symptomatology improvement in MDD patients.
In this study, we have excluded potential confounding factors by making comparisons of the demographic data, including gender, age and residential locations, between the MDD group and control group, and then within the MDD group. There were no differences in age, sex or residential locations between MDD patients and healthy controls nor within the MDD group. However, we found that the changes of four differentially expressed miRNAs (miR-1972, miR-4485, miR-4498 and miR-4743) were positively correlated with the improvement of retardation after six-week antidepressant medication. As the HAMD score lowered along the medication course, the symptoms improved, Table 5 Correlation of miRNA expression alteration and HAMD and GI score changes before and after antidepressants treatment. and the expression levels of miRNAs down regulated. Logistic regression analysis further revealed that the expression of miR-4498 was apparently linearly related to retardation score. These five differentially expressed miRNAs have been scarcely reported before. According to Fan 38 , there was a significant enrichment in several pathways associated with brain functions and nervous system, supporting the hypothesis that differentiallyregulated miRNAs may be involved in mechanism underlying development of MDD. On the other hand, the change of miR-26b expression was also found to be negatively correlated with the day and night factor score change, which indicated that the higher of the expression level of miR-26b was, the more severe the day and night change symptom would be. According to Absalon 39 , ectopic overexpression of miR-26b in rat primary postmitotic neurons led to the DNA replication and aberrant Cell Cycle Entry (CCE) and, in parallel, increased tau-phosphorylation, which culminated in the apoptotic cell death of neurons 39 42 . These studies have involved these five miRNAs in different diseases, but that how exactly are these five miRNAs involved in depression remains unclear. The newly discovered miRNAs that are potentially involved in the molecular and cellular mechanism of depression underscore the significance of this study. More studies are warranted to further explore the mechanism pathways of depression.
In conclusion, miR-4743, miR-4498, miR-4485, miR-1972 and miR-26b are potentially involved in pathogenesis of MDD, and may serve as therapeutic targets of antidepressant drugs. The specific mechanism underlying this interaction warrants further investigation.
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